Recursion Pharmaceuticals (RXRX)
(Delayed Data from NSDQ)
$6.12 USD
+0.20 (3.38%)
Updated Sep 9, 2024 04:00 PM ET
After-Market: $6.12 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Earnings News For RXRX
-
CORRECTION - Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results
-
Recursion Pharmaceuticals (RXRX) Reports Q2 Loss, Tops Revenue Estimates
-
Recursion Pharmaceuticals: Q2 Earnings Snapshot
-
Recursion (RXRX) to Report Q2 Earnings: What's in the Cards?
-
Recursion Pharmaceuticals: Q1 Earnings Snapshot
-
Recursion Pharmaceuticals (RXRX) Reports Q1 Loss, Tops Revenue Estimates
-
Recursion Provides Business Updates and Reports First Quarter 2024 Financial Results
-
Recursion (RXRX) to Report Q1 Earnings: What's in the Cards?
-
Recursion Pharmaceuticals: Q4 Earnings Snapshot
-
Recursion Pharmaceuticals (RXRX) Reports Q4 Loss, Lags Revenue Estimates
-
Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2023 Financial Results
-
Analysts Estimate Recursion Pharmaceuticals (RXRX) to Report a Decline in Earnings: What to Look Out for
-
Recursion Pharmaceuticals: Q3 Earnings Snapshot
-
Recursion Provides Business Updates and Reports Third Quarter 2023 Financial Results
-
Recursion Pharmaceuticals (RXRX) Reports Q2 Loss, Tops Revenue Estimates
-
Recursion Pharmaceuticals: Q2 Earnings Snapshot
-
Recursion Provides Business Updates and Reports Second Quarter 2023 Financial Results
-
Recursion Pharmaceuticals (RXRX) Reports Q1 Loss, Lags Revenue Estimates
-
Recursion Pharmaceuticals: Q1 Earnings Snapshot
-
Recursion Provides Business Updates and Reports First Quarter 2023 Financial Results
-
Recursion Pharmaceuticals (RXRX) Reports Q4 Loss, Misses Revenue Estimates
-
Recursion Pharmaceuticals: Q4 Earnings Snapshot
-
Recursion Pharmaceuticals (RXRX) Reports Q3 Loss, Tops Revenue Estimates
-
Recursion Pharmaceuticals: Q3 Earnings Snapshot
-
Recursion Provides Business Updates and Reports Third Quarter 2022 Financial Results